

**Increased healthcare costs associated with frailty among community-dwelling older people: A systematic review and meta-analysis.**

Gotaro Kojima, MD<sup>1,2</sup>.

1 Videbimus Toranomom Clinic, Tokyo, Japan

2 Department of Primary Care and Population Health, University College London, London, UK

Corresponding Author:

Gotaro Kojima, MD

Videbimus Toranomom Clinic

Shimbashi Plaza Building 2F

4-9-1 Shimbashi, Minato-ku, Tokyo 105-0004

Phone: +81-(0)3-6447-5018

Fax: +81-(0)3-6447-5267

Email: [gotarokojima@yahoo.co.jp](mailto:gotarokojima@yahoo.co.jp)

Keywords: Frailty; Frail Elderly; Costs and cost analysis; Health care costs; Health Expenditures; Systematic review.

## ABSTRACT

**Background:** Although frailty of older people has been shown to be associated with numerous adverse health outcomes, evidence on healthcare costs associated with frailty is scarce.

**Methods:** Medline, Embase, PsycINFO, and AMED were electronically searched in January 2019 based on a protocol in accordance with the PRISMA statement using Medical Subjective Heading and free text terms, with explosion functions. Language restriction was not applied. Studies were considered if they were published between 2000 to January 2019 and provided healthcare costs stratified by the frailty status categories among community-dwelling older people with a mean age of 60 years or higher. Reference lists of the included studies were reviewed for additional studies. Healthcare costs according to frailty status were compared using standardized mean difference random-effects meta-analysis.

**Results:** The systematic review found 3116 citations. After screening for title, abstract, and full-text for eligibility, 5 studies involving 3742362 participants were included. Healthcare costs were compared across three frailty status, robust, prefrailty, and frailty. Both prefrailty (5 studies, Hedges'  $g=0.24$ , 95% confidence interval (CI)=0.15-0.33,  $p<0.001$ ) and frailty (5 studies, Hedges'  $g=0.62$ , 95%CI=0.61-0.62,  $p<0.001$ ) were associated with significantly higher healthcare costs when compared with robustness. There was a high degree of heterogeneity. The risk of publication bias was considered to be low in funnel plots.

**Conclusions:** This systematic review and meta-analysis found a dose-response increase in the healthcare costs associated with frailty among community-dwelling older adults. Future research should recognize frailty as an important factor associated with increased healthcare costs.

## **INTRODUCTION**

Over the last century, life expectancy has steadily improved worldwide and the number and proportion of older people have markedly increased.<sup>1</sup> This trend is expected to continue in the next few decades and there will be an unprecedentedly large number of older people.<sup>1</sup>

Older adults are the main users of healthcare services and account for the majority of the healthcare costs.<sup>2</sup> As people age, they generally tend to develop more health problems, such as chronic diseases, physical and cognitive functional declines, and disabilities, and therefore, require various healthcare resources. In the US, Medicare spending per capita by age steadily increased from 65 years old (mean 5,562 USD) and almost tripled by the age of 96 (mean 15,732 USD).<sup>3</sup>

A few recent studies have suggested that frailty is associated with increased use of healthcare resources and higher healthcare costs among older adults.<sup>4</sup> Frailty is conceptually defined as a clinically recognizable state characterized by a compromised ability of older people to tolerate stressors and increased vulnerability due to age-related accumulated health deficits in multiple physiological systems.<sup>5,6</sup> Frail older adults are at an increased risk of various negative health outcomes, including falls,<sup>7</sup> disabilities,<sup>8,9</sup> dementia,<sup>10</sup> and mortality.<sup>11-13</sup> Frailty is also associated with increased use of healthcare resources, such as emergency department visits,<sup>14</sup> hospitalization,<sup>15</sup> and institutionalization.<sup>16,17</sup> In light of these significant negative impacts on older adults as well as burdens on healthcare systems and the growing number of older adults in an aging population, frailty has been recognized as a public health priority.<sup>4,18</sup> However there are only a limited amount of evidence found in the literature regarding the healthcare costs associated with frailty.

The objectives of this study are to conduct a systematic review of the literature for the available evidence on the association between frailty and healthcare costs among community-dwelling older adults and to synthesize pooled estimates of excess healthcare costs due to frailty by meta-analysis.

## **METHOD**

### **Data source and search strategy**

A systematic review of the literature was performed by one investigator (GK) on January 20<sup>th</sup> 2019 for studies that were published between January 2000 and January 2019 in four electronic databases (Embase, Medline, PsycINFO, and AMED). A protocol was developed a priori according to the PRISMA statements<sup>19</sup> and registered at PROSPERO ([http://www.crd.york.ac.uk/PROSPERO/display\\_record.php?ID=CRD42019123101](http://www.crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD42019123101)). A combination of Medical Subjective Heading (MeSH) and free text terms was used for the search with explosion functions and without language restriction. The search terms used were: [Frailty (MeSH) OR Frail elderly (MeSH) OR “frailty”] AND [Costs and cost analysis (MeSH) OR Health care cost(s) (MeSH) OR Health expenditures (MeSH) OR Cost (MeSH) OR “cost\*” OR “economic\*” OR “expenditure\*” OR “expense\*” OR “finance\*” OR “monetary” OR “payment\*” OR “reimburs\*”]. Additionally, the reference lists of the included studies were hand-searched. Corresponding authors were contacted for the data necessary for the meta-analysis if needed.

### **Study Selection**

Studies were considered to be eligible and were included if (1) they used community-dwelling older people with a mean age of 60 years or higher, (2) divided the cohort into two (non-frail, frail) or three (robust, prefrail, frail) groups based on a validated frailty definition or modified versions of it, and (3) provided healthcare costs before or after the baseline

(including prevalent costs or incidental costs) stratified by the frailty status categories. Studies were excluded if they (1) used a selected sample, such as patients with a specific medical condition, (2) used a continuous score to define frailty, such as the Frailty Index, or (3) were reviews, randomized controlled trials, editorials, letters to the editor, comments, or dissertations. Titles, abstracts, and full-texts of the studies found through the review of the literature were screened for eligibility by one investigator (GK) according to the inclusion and exclusion criteria. When two or more studies used the same cohort, the one with the largest sample size was chosen for meta-analysis.

### **Data Extraction**

Data extracted from each of the studies were: first author, study or cohort name, publication year, location, sample size, proportion of female participants, age, frailty definition, and healthcare costs by frailty status.

### **Methodological Quality Assessment**

Methodological quality of the studies was appraised by one investigator (GK) using the Joanna Briggs Institute Critical Appraisal Checklist for Analytical Cross-Sectional Studies,<sup>20</sup> which consists of 8 items to be answered either “Yes”, “No”, “Unclear”, or “Not applicable”. The number of “Yes” responses was summed to make a score, ranging from 0 to 8, with a higher score indicative of better methodological quality. A score of 4 or more was considered to be adequate methodological quality.

### **Statistical Analysis**

#### ***Standardized mean difference***

The healthcare costs of prefrail and frail groups were separately compared with that of robust group by calculating a standardized mean difference (SMD) of the healthcare costs as Hedges’ g, weighted according to the sample size of the studies. Hedges’ g was calculated from the mean, standard deviation, and sample size from each study, and the positive effect size is suggestive of higher healthcare costs in prefrail or frail groups than in the robust group. The magnitude of Hedges’ g was interpreted as small (0.2), medium (0.5), and large (0.8) by Cohen’s convention.<sup>21</sup> Heterogeneity across the studies was examined using a chi-square test and its degree was assessed using I<sup>2</sup> statistic. If there was a significant heterogeneity, a random-effect meta-analysis was used, and a fixed-effect meta-analysis was used if not. If a high degree of heterogeneity was identified, a subgroup analysis, a sensitivity analysis, and a meta-regression analysis were used to explore the reasons for the high heterogeneity. Publication bias was assessed by visually inspecting a funnel plot.


Statistical analyses were conducted using the Review Manager 5 (Version 5.2, The Cochrane Collaboration, Copenhagen, Denmark). All analyses were two-sided and p<0.05 was considered as statistically significant.

## **RESULTS**

### **Selection Processes**

The systematic review identified a total of 3,116 studies (2,248 from Embase, 654 from Medline, 184 from PsycINFO, and 30 from AMED), one study was found from other source. After 786 duplicate studies were removed, 2,331 studies were left for title, abstract, and full-text for eligibility. Finally, 5 studies involving a total of 3,742,362 participants were included in this review.<sup>22-25</sup> A flow chart of the systematic review was shown in **Figure 1**. Characteristics of the included studies are presented in **Table 1**.

**Figure 1.** Flow chart of systematic literature review.



**Table 1.** Summary of included studies on frailty and healthcare costs among community-dwelling older people

First author/ Year/Study	Location	Sample size	Female (%)	Age (range)	Frailty definition	Healthcare costs (currency)	Mean (SD) n		
							Robust	Prefrail	Frail
Salinas- Rodriguez 2019	Mexico	265	72%	80.5	mCHS	Annual total of direct costs (health resources and services) and indirect costs (loss of labor productivity). (Mexican pesos)	32401.21 (34286.51) n=89	45825.04 (48655.34) n=132	64951.17 (68835.21) n=44
Simpson 2019	US	3,736,540	58.9%	79.9 (≥65)	Faurot frailty index	9-month total of inpatient hospital payments, outpatient services, and prescription medications. (US dollar)	8100 (25082) n=2,795,550	16305 (38058) n=738,462	25320 (53066) n=202,528
Ensrud 2018 SOF	US	2,150	100%	80.2 (≥65)	mCHS	12-month total of acute hospital stays, skilled nursing facility stay paid under Medicare Part A, inpatient rehabilitation facility stays, outpatient care, and home health care. (US dollar)	3781 (6920) n=554	6632 (12452) n=1,188	10755 (16589) n=408
Garcia- Nogueras 2017 FRADEA	Spain	818	37.1%	75.8 (≥70)	mCHS	Annual total of costs for hospital admissions, specialist visits, and emergency visit. (Euro)	1217 (2170) n=213	2056 (3496) n=457	2476 (3433) n=160
Bock 2016 ESTHER	Germany	2,589	51.5%	69.6 (57-84)	mCHS	3-month total of inpatient treatment, outpatient treatment, medical supplies, dental protheses, pharmaceuticals, and formal and informal nursing care. (Euro)	642 (1546) n=876	821 (1846)* n=1,506	2258 (4604)* n=207

\* Calculated from available data

GFI: Groningen Frailty Indicator

mCHS: modified Cardiovascular Health Study criteria.

SD: Standard deviation

SOF: Study of Osteoporotic Fractures

### **Methodological Quality Assessment and publication bias**


All included studies were assessed for their methodological quality. The scores ranged from 5 to 8, with a mean of 6.8, and all studies were considered to have adequate methodological quality. Although it was difficult to visually assess forest plots as only five studies were included, there seemed to be no apparent asymmetry in the two forest plots for prefrailty and frailty, respectively compared with the robustness, the risk of publication bias was considered to be low.

### **Meta-analysis of healthcare costs by frailty status**

Healthcare costs according to the three frailty status groups (robust, prefrail, frail) were available from five studies,<sup>22-26</sup> and pooled using a random-effect meta-analysis based on a high degree of heterogeneity ( $I^2=80\%$ ,  $p<0.001$  for prefrail). Both frailty (5 studies, Hedges'  $g=0.62$ , 95%CI=0.61-0.62,  $p<0.001$ ) and prefrailty (5 studies, Hedges'  $g=0.24$ , 95% confidence interval (CI)=0.15-0.33,  $p<0.001$ ) were associated with significantly higher healthcare costs when compared with robustness (**Figure 2**). The higher the degree of frailty was, the more healthcare costs were spent ( $p$  for differences between frailty and prefrailty groups $<0.001$ ). Subgroup analysis, sensitivity analysis, and meta-regression analysis were not considered due to the small number of studies included.


**Figure 2.** Standardized mean difference of healthcare costs of frail (A) and prefrail (B), compared with robust.

**A. Frail vs. Robust**



(The pooled standardized mean difference is not shown due to technical reason)

**B. Prefrail vs. Robust**



## DISCUSSION

This is the first attempt to describe the association between frailty and healthcare costs among community-dwelling older adults by conducting a systematic review and meta-analysis. The systematic review identified five studies encompassing a total of 3,742,362 participants and the meta-analysis showed a positive association between frailty and healthcare costs in a dose-response manner, regardless of lower power due to the small number of included studies. It should also be noted that, although the included studies examined various types of healthcare costs over different time ranges, higher degree of frailty was consistently shown to be associated with higher healthcare costs.

One of the five included studies used a cohort of more than 3.6 million Medicare beneficiaries.<sup>25</sup> Because the number of participants was substantially larger than those of the other studies ( $n=265-2,589$ ), the findings of this study were heavily weighted in the random-effects meta-analyses especially for the frail vs. robust analysis (99.7% in frail vs. robust, 30.3% for prefrail vs. robust). However, the standardized mean difference did not change significantly when this study was removed; frail vs. robust Hedges'  $g=0.62$  (95% CI=0.61-0.62)  $\rightarrow 0.59$  (95% CI=0.50-0.68), prefrail vs. robust Hedges'  $g=0.24$  (95% CI=0.15-0.33)  $\rightarrow 0.21$  (95% CI=0.11-0.32).

While four studies were from high income countries, only one study was from low-/middle-income country.<sup>26</sup> There was no significant subgroup difference between the four studies from high-income countries and the one study from Mexico; frail vs. robust  $p=0.78$ , prefrail vs. robust  $p$  for difference=0.59.

It seems that frailty plays an important role in terms of healthcare costs possibly through increasing risks of use of healthcare resources.<sup>14, 15, 17</sup> In a study by Bock et al., frailty was significantly associated with total healthcare costs even after controlling for comorbidity in a multivariate regression model, where age was not associated with healthcare costs when frailty was in the model.<sup>22</sup> Ensrud et al. showed that prefrailty and frailty were both significantly associated with higher healthcare costs than robustness, controlling for confounders including age, comorbidity, and functional limitations.<sup>23</sup> Another study of 1,284 French older adults showed that frail and prefrail participants had a significantly higher ambulatory healthcare expenditures when compared with the robust participants in a multivariate generalized linear model controlling for age, the number of chronic diseases and activities of daily living (ADL) limitations, and other factors, where age was not significantly associated with healthcare costs.<sup>27</sup> As shown in these studies, significant associations between frailty and increased healthcare costs seems independent of age, comorbidity, or disability.

One of the main strengths was that this study was conducted based on a priori protocol in accordance with the PRISMA statements. The other strengths include the reproducible search strategy of the systematic review using comprehensive search terms including MeSH terms and that methodological quality and publication bias were examined. Additional data were obtained from authors of the original study and were included in the meta-analysis. Lastly, all the included studies are peer-reviewed original contributions.

There are some limitations that should be taken into account. First, there was significant heterogeneity across the included studies, which used different frailty definitions and methodologies to quantify healthcare costs. Therefore, a standardized mean difference was calculated using a random-effect meta-analysis. Regardless of the heterogeneity, the studies showed consistently higher healthcare costs among frailer participants and the meta-analysis

found a significant positive association between frailty and healthcare costs. Second, only one investigator was involved in all the processes, therefore some important studies may have been missed. Third, due to the limited number of studies included, subgroup analysis, sensitivity analysis, and meta-regression analysis were not conducted. Fourth, gray literature was not considered in the current review.

### **Conclusion**

In conclusion, this systematic review and meta-analysis found a dose-response increase in the healthcare costs associated with frailty among community-dwelling older adults. The association between frailty and healthcare costs has significant implications given its spontaneous reversibility<sup>28, 29</sup> and improvement by exercise and/or nutritional supplementation.<sup>30</sup> In future research, frailty should be recognized an important factor associated with increased healthcare costs.

### **FUNDING**

None.

### **CONFLICTS OF INTEREST STATEMENT**

Author does not have conflict of interest to report.

### **ACKNOWLEDGEMENTS**

Author appreciates additional data shared by an author of original article.<sup>26</sup>

### **REFERENCES**

1. World Health Organization, World Health Day 2012, Are you ready? What you need to know about ageing; 2012. <http://www.who.int/world-health-day/2012/toolkit/background/en/>. Accessed 2 March 2016.
2. Rockwood, K, Hubbard, R. Frailty and the geriatrician. *Age and ageing* 2004;33(5):429-430.
3. The Rising Cost of Living Longer: Analysis of Medicare Spending by Age for Beneficiaries in Traditional Medicare, Henry Kaiser Family Foundation; 2015. <https://www.kff.org/medicare/report/the-rising-cost-of-living-longer-analysis-of-medicare-spending-by-age-for-beneficiaries-in-traditional-medicare/>. Accessed 27 January 2019.
4. Kojima, G, Liljas, A, Iliffe, S. Frailty Syndrome: implications and challenges for healthcare policy. *Risk management and healthcare policy* 2019.
5. Clegg, A, Young, J, Iliffe, S, et al. Frailty in elderly people. *Lancet (London, England)* 2013;381(9868):752-762.
6. Morley, JE, Vellas, B, van Kan, GA, et al. Frailty consensus: a call to action. *Journal of the American Medical Directors Association* 2013;14(6):392-397.
7. Kojima, G. Frailty as a Predictor of Future Falls Among Community-Dwelling Older People: A Systematic Review and Meta-Analysis. *Journal of the American Medical Directors Association* 2015;16(12):1027-1033.
8. Kojima, G. Frailty as a predictor of disabilities among community-dwelling older people: a systematic review and meta-analysis. *Disability and rehabilitation* 2017;39(19):1897-1908.
9. Kojima, G. Quick and Simple FRAIL Scale Predicts Incident Activities of Daily Living (ADL) and Instrumental ADL (IADL) Disabilities: A Systematic Review and Meta-analysis. *Journal of the American Medical Directors Association* 2018.

10. Kojima, G, Taniguchi, Y, Iliffe, S, et al. Frailty as a Predictor of Alzheimer Disease, Vascular Dementia, and All Dementia Among Community-Dwelling Older People: A Systematic Review and Meta-Analysis. *Journal of the American Medical Directors Association* 2016;17(10):881-888.
11. Kojima, G. Frailty defined by FRAIL scale as a predictor of mortality: A systematic review and meta-analysis. *Journal of the American Medical Directors Association* 2018;19(6):480-483.
12. Kojima, G, Iliffe, S, Walters, K. Frailty index as a predictor of mortality: a systematic review and meta-analysis. *Age and ageing* 2018;47(2):193-200.
13. Kojima, G, Taniguchi, Y, Kitamura, A, et al. Are the Kihon Checklist and the Kaigo-Yobo Checklist compatible with the Frailty Index? *Journal of the American Medical Directors Association* 2018;19(9):797-800.
14. Kojima, G. Frailty as a Predictor of Emergency Department Utilization among Community-Dwelling Older People: A Systematic Review and Meta-Analysis. *Journal of the American Medical Directors Association* 2018.
15. Kojima, G. Frailty as a predictor of hospitalisation among community-dwelling older people: a systematic review and meta-analysis. *Journal of epidemiology and community health* 2016;70(7):722-729.
16. Kojima, G. Prevalence of Frailty in Nursing Homes: A Systematic Review and Meta-Analysis. *Journal of the American Medical Directors Association* 2015;16(11):940-945.
17. Kojima, G. Frailty as a Predictor of Nursing Home Placement among Community-Dwelling Older Adults: A Systematic Review and Meta-analysis. *Journal of Geriatric Physical Therapy* 2018;41(1):42-48.
18. Cesari, M, Prince, M, Thiyagarajan, JA, et al. Frailty: An Emerging Public Health Priority. *Journal of the American Medical Directors Association* 2016;17(3):188-192.
19. Moher, D, Liberati, A, Tetzlaff, J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *BMJ (Clinical research ed)* 2009;339:b2535.
20. Critical Appraisal Tools, Joanna Briggs Institute; <http://joannabriggs.org/research/critical-appraisal-tools.html>. Accessed 28 January 2019.
21. Cohen, J. *Statistical Power Analysis for the Behavioral Sciences*, Second Edition. Routledge, 1988.
22. Bock, JO, Konig, HH, Brenner, H, et al. Associations of frailty with health care costs- results of the ESTHER cohort study. *BMC health services research* 2016;16:128.
23. Ensrud, KE, Kats, AM, Schousboe, JT, et al. Frailty Phenotype and Healthcare Costs and Utilization in Older Women. *Journal of the American Geriatrics Society* 2018;66(7):1276-1283.
24. Garcia-Nogueras, I, Aranda-Reneo, I, Pena-Longobardo, LM, et al. Use of Health Resources and Healthcare Costs associated with Frailty: The FRADEA Study. *The journal of nutrition, health & aging* 2017;21(2):207-214.
25. Simpson, KN, Seamon, BA, Hand, BN, et al. Effect of frailty on resource use and cost for Medicare patients. *Journal of comparative effectiveness research* 2018.
26. Salinas-Rodriguez, A, Manrique-Espinoza, B, Heredia-Pi, I, et al. Healthcare Costs of Frailty: Implications for Long-term Care. *Journal of the American Medical Directors Association* 2019;20(1):102-103.e102.
27. Sirven, N, Rapp, T. The cost of frailty in France. *The European journal of health economics : HEPAC : health economics in prevention and care* 2017;18(2):243-253.

28. Kojima, G, Taniguchi, Y, Iliffe, S, et al. Transitions between frailty states among community-dwelling older people: A systematic review and meta-analysis. *Ageing research reviews* 2019;50:81-88.
29. Kojima, G, Taniguchi, Y, Iliffe, S, et al. Factors associated with improvement in frailty status defined using the frailty phenotype: A systematic review and meta-analysis. *Journal of the American Medical Directors Association* 2019.
30. Lozano-Montoya, I, Correa-Perez, A, Abraha, I, et al. Nonpharmacological interventions to treat physical frailty and sarcopenia in older patients: a systematic overview - the SENATOR Project ONTOP Series. *Clinical interventions in aging* 2017;12:721-740.